~~<i id='1D65A45E6B'><strike id='1D65A45E6B'><tt id='1D65A45E6B'><pre id='1D65A45E6B'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：explore 2025-10-03 00:58:41 Page View：97542

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Buoyed by wins on obesity, Novo Nordisk eyes heart disease
Next article： Peter Hotez and the public health issue of online harassment

leisure time

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Why 40% Americans with Parkinson’s don’t see a neurologist

RichardHuckabee,seenwithhiswife,Angela,saysittooknineyearstobediagnosedwithParkinson’s.CourtesyRicha

Alkermes shareholders re

MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

KenaBetancur/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbi